Navigation Links
Elekta Chosen to Deliver Sophisticated Brain Mapping Technology to Froedtert Hospital in Milwaukee
Date:3/10/2008

ATLANTA and MILWAUKEE, March 10 /PRNewswire/ -- Elekta Neuromag(R), the world-leading equipment for non-invasive measurement of brain activity using Magnetoencephalography (MEG) technology, has been ordered by Froedtert Memorial Lutheran Hospital.

(Logo: http://www.newscom.com/cgi-bin/prnh/20020318/ELEKTALOGO )

Located in the western suburbs of Milwaukee, Froedtert Hospital has played a critical role in the quality of life in Wisconsin and Northern Illinois since opening its doors in 1980 as a not-for-profit hospital. More than 800 Medical College of Wisconsin physicians and more than 4,000 staff members are dedicated to excellence in patient care, research and medical education at this premier academic medical center.

Froedtert Hospital will receive its new Elekta Neuromag MEG system in the autumn of 2008. With the MEG system from Elekta installed, neurosurgeons, neurologists and those in related fields will be able to non-invasively record human brain activity in real time, better and more accurately than ever before.

MEG technology is regarded as the most efficient method for tracking brain activity at millisecond resolution. Compared to EEG technology, MEG has uniquely accurate localization capabilities. Other technologies, for example Computed Tomography (CT) and Magnetic Resonance Imaging (MRI), provide only anatomical or metabolic information; whereas MEG is a direct measure of neuronal electric activity. When complemented with MRI, MEG increases the ability to understand brain activity and to improve treatment of functional disorders and, in particular, epilepsy.

"We look forward to soon becoming the site of the first whole-head Magnetoencephalography lab in the state," says Elizabeth Ragalie, Director of the Neurosciences Center at Froedtert Hospital. "We intend to use the MEG in our epilepsy program as a powerful new tool for pre-surgical planning. The non-invasive and fast measurement capability of the technology is well suited to the high-quality patient care and advancement of scientific discovery that we strive to achieve here at Froedtert." Ragalie went on to say, "Furthermore, we plan to launch an ambitious research program in conjunction with the Medical College of Wisconsin, which will make use of the unique temporal resolution of MEG technology. We chose the Elekta Neuromag MEG system because its combination of sensitive detectors, robust environmental noise cancellation and versatile software was deemed best able to meet the stringent demands of our users."

"With leading technology to the development of MEG technology and methodology, Elekta was the natural choice when Froedtert made its decision," says Gordon Haid, Director of MEG Sales for North America. "We are pleased to see an increasing interest around the world for Elekta Neuromag systems, particularly in the US."

Elekta Neuromag(R)

The Elekta Neuromag 306-channel MEG sensor array has a higher density of detectors than any other system on the market, leading to a more accurate representation of brain activity. The industry's lowest signal-to-noise ratio means that more useful information is acquired, thus yielding the highest information per sample.

The unique design of the sensors combined with advanced software makes it possible to gain data with unsurpassed detail, even from the deepest regions of the brain. The system also has the highest available immunity to magnetic interference, either patient-related or external. Elekta Neuromag also has the lowest operational costs. Elekta Neuromag is technically the most sophisticated MEG/EEG device available on the market today.

About Elekta

Elekta is an international medical technology group, providing oncologists, radiation therapists, neurosurgeons and many other medical specialists with state of the art tools to fight serious disease.

Elekta provides advanced clinical solutions, comprehensive management and information systems as well as services for improved cancer care and management of brain disorders.

Elekta's systems and solutions are used in over 4,500 hospitals around the world. Clinical and information management solutions include, among others, Leksell Gamma Knife(R) for non-invasive treatment of brain disorders, Elekta Axesse(TM) and Elekta Synergy(R) for stereotactic and image guided radiation therapy and radiosurgery as well as the MOSAIQ(TM) suite of software for image-enabled EMR and efficient management of clinical and patient data.

With over 2,000 employees globally, the corporate headquarter is located in Stockholm, Sweden and the company is listed on the Nordic Exchange under the ticker EKTAb. More information about Elekta can be found at http://www.elekta.com.


'/>"/>
SOURCE Elekta, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Johns Hopkins to add Elekta Synergy S(R) to Cancer Treatment Lineup
2. Elekta Demonstrates Commitment to Stereotactic Innovation at EANS
3. Elekta To Showcase Innovations in Radiotherapy and Unveil New Product That Expands Cancer Treatment Availability
4. Elekta Contract Provides Sisters of Mercy Health System Access to Leading Radiation Therapy Solutions
5. Elekta Launches New Linear Accelerator at 2007 ESTRO to Expand Cancer Treatment Availability
6. Elekta Brings Intelligent Ways to Manage Motion During Cancer Treatment to ESTRO
7. Elekta Displays Complete Volumetric Intensity Modulated Arc Therapy Solutions at ESTRO
8. Elekta Announces New Cancer Care Solutions and Highlights Personalized Efficiency at ASTRO 2007
9. Elekta Announces Elekta Infinity - a New System for Faster and More Precise Treatment of Cancer Tumors
10. Beaumont Hospital, Royal Oak Treats Its First Patients With Elekta Axesse
11. Elekta Showcases Stereotactic Systems for Cancer Care at Astro 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... Newly created 4Sight Medical ... to the healthcare market. The company's primary focus is on new product introductions, ... strategies that are necessary to help companies efficiently bring their products to market. ...
(Date:6/24/2016)... , June 24, 2016 Epic ... sensitively detects cancers susceptible to PARP inhibitors by ... tumor cells (CTCs). The new test has already ... therapeutics in multiple cancer types. Over ... DNA damage response pathways, including PARP, ATM, ATR, ...
(Date:6/23/2016)... 2016   Boston Biomedical , an industry ... to target cancer stemness pathways, announced that its ... Drug Designation from the U.S. Food and Drug ... including gastroesophageal junction (GEJ) cancer. Napabucasin is an ... cancer stemness pathways by targeting STAT3, and is ...
(Date:6/23/2016)... Prostate Cancer Foundation (PCF) is pleased to announce 24 new Young ... cancer. Members of the Class of 2016 were selected from a pool of ... More About the Class of 2016 PCF Young Investigators ... ... ...
Breaking Biology Technology:
(Date:4/19/2016)... DUBAI , UAE, April 20, 2016 ... can be implemented as a compact web-based "all-in-one" system ... in the biometric fingerprint reader or the door interface ... requirements of modern access control systems. The minimal dimensions ... the ID readers into the building installations offer considerable ...
(Date:4/14/2016)... , April 14, 2016 ... and Malware Detection, today announced the appointment of ... the new role. Goldwerger,s leadership appointment comes ... the heels of the deployment of its platform at ... behavioral biometric technology, which discerns unique cognitive and physiological ...
(Date:3/31/2016)... , March 31, 2016  Genomics firm Nabsys has ... CEO, Barrett Bready , M.D., who returned to ... the original technical leadership team, including Chief Technology Officer, ... Product Development, Steve Nurnberg and Vice President of Software ... the company. Dr. Bready served as CEO ...
Breaking Biology News(10 mins):